Every 8-K that FibroGen, Inc (FGEN) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow FGEN and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full FGEN filings page.
Kyntra Bio, Inc. received $4.0 million from AstraZeneca Treasury Limited on June 2, 2026. This payment represents the second and final holdback under their February 20, 2025 share purchase agreement covering the sale of Kyntra’s China operations.
The China business was sold to AstraZeneca on August 29, 2025 for total consideration of approximately $220 million, including $85 million in enterprise value and about $135 million in net cash held in China. Kyntra had previously collected $210 million at closing and a first holdback of $6.0 million plus an additional $0.4 million after final net cash adjustments. With this latest $4.0 million payment, the company has now received all amounts owed under the agreement.
Kyntra Bio reported first quarter 2026 results, showing total revenue from continuing operations of $3.7 million, up from $2.7 million a year earlier, driven mainly by higher drug product revenue. Net loss from continuing operations narrowed to $15.1 million, or $3.74 per share, compared with a $16.8 million loss, or $4.15 per share, in 2025.
The company ended March 31, 2026 with $100.3 million in cash, cash equivalents, investments, and accounts receivable and expects this to fund its operating plans into 2028. Kyntra highlighted steady progress in its pipeline, including an actively enrolling Phase 2 trial of FG-3246 in metastatic castration-resistant prostate cancer with an interim analysis planned for the fourth quarter of 2026, and finalization of a pivotal Phase 3 roxadustat protocol in lower-risk myelodysplastic syndromes ahead of a targeted trial start in the second half of 2026.
Kyntra Bio, Inc. reported receiving a Nasdaq notice on April 2, 2026 that it no longer meets the Nasdaq Global Select Market continued listing requirement of $50 million in total assets and total revenue under Listing Rule 5450(b)(3)(A).
The shortfall arises because revenue of FibroGen International is now presented as held for sale in discontinued operations for 2024 and 2025, and the company also does not meet the alternative shareholders’ equity or market value standards. Kyntra Bio has 45 days, until May 18, 2026, to submit a plan to regain compliance, and Nasdaq may grant up to a 180‑day extension to September 29, 2026 if the plan is accepted.
Kyntra Bio reported fourth quarter and full-year 2025 results and highlighted progress in its oncology and rare disease pipeline. The company is running a Phase 2 monotherapy trial of FG-3246 in metastatic castration-resistant prostate cancer, with an interim analysis planned in the second half of 2026, and reported encouraging investigator-sponsored combination data with enzalutamide presented at ASCO meetings.
Kyntra submitted a pivotal Phase 3 protocol for roxadustat in anemia due to lower-risk myelodysplastic syndromes to the FDA and is evaluating whether to advance this program alone or with a partner. Total revenue from continuing operations fell to $6.4 million in 2025 from $29.6 million in 2024, but the net loss from continuing operations narrowed to $58.2 million from $153.1 million, reflecting a restructuring and portfolio shift. The company ended 2025 with $109.4 million in cash, cash equivalents, investments, and accounts receivable and currently expects this to fund operating plans into 2028.
FibroGen, Inc. has changed its corporate name to Kyntra Bio, Inc. following the filing of a Certificate of Amendment to its Amended and Restated Certificate of Incorporation with the State of Delaware on December 29, 2025. The name change becomes effective at 4:30 p.m. Eastern Time on January 7, 2026.
The board also approved a conforming amendment to the company’s Bylaws, effective at the same time, to update the Bylaws’ title to Kyntra Bio, Inc. In connection with the rebranding, the company’s common stock, previously trading under the symbol “FGEN” on The Nasdaq Global Select Market, will begin trading under the new symbol “KYNB” at the market open on January 8, 2026. The CUSIP number for the common stock remains unchanged.
FibroGen, Inc. furnished an 8-K to announce it issued a press release with financial results for the quarter ended September 30, 2025. The press release is provided as Exhibit 99.1.
The company states the information under Item 2.02, including Exhibit 99.1, is not deemed “filed” under the Exchange Act and will not be incorporated by reference into other SEC filings.
FibroGen, Inc. reported receipt of a $6.4 million payment from AstraZeneca. The amount reflects release of the first $6.0 million holdback under their February 20, 2025 share purchase agreement, plus $0.4 million from final net cash adjustments after closing.
This relates to FibroGen’s August 29, 2025 sale of its China operations to AstraZeneca for approximately $220 million, comprised of $85 million in enterprise value and about $135 million in net cash held in China. Of the total, $210 million was paid at closing, with an additional $10.0 million subject to holdbacks: the now-released $6.0 million cash-adjustment holdback and a separate $4.0 million indemnity holdback to be released, net of any claims paid or unresolved, nine months after closing.
FibroGen, Inc. completed the sale of all issued and outstanding equity interests of its subsidiary FibroGen International (Hong Kong) Ltd. to AstraZeneca Treasury Limited on August 29, 2025 for approximately $220 million, closing a previously announced transaction under a Share Purchase Agreement dated February 20, 2025. The deal represents a disposition of assets associated with FibroGen’s China anemia business structure. The company also provided unaudited pro forma condensed consolidated financial information, including a balance sheet as of June 30, 2025 and statements of operations for the year ended December 31, 2024, in Exhibit 99.1 to help illustrate the financial impact of this divestiture.
FibroGen, Inc. reported that it has completed the sale of FibroGen International (Hong Kong) Ltd., including its FibroGen China operations, to AstraZeneca Treasury Limited for total consideration of approximately $220 million. This amount consists of $85 million in enterprise value and about $135 million in net cash held in China, with $6.0 million held back for final cash adjustments and $4.0 million held back for potential indemnity claims.
FibroGen and a subsidiary sold all equity interests in the Hong Kong entity and its China roxadustat assets to AstraZeneca, which has long partnered with FibroGen on roxadustat in greater China and South Korea. FibroGen keeps roxadustat rights in the United States, Canada, Mexico, and other territories not held by AstraZeneca or licensed to Astellas Pharma Inc. At closing, FibroGen repaid its term loan facility with investment funds managed by Morgan Stanley Tactical Value for approximately $81 million.
FibroGen, Inc. announced that Chinese regulators approved the proposed sale of FibroGen International (Hong Kong) Ltd. and its subsidiaries (“FibroGen China”) to AstraZeneca Treasury Limited under a share purchase agreement dated February 20, 2025.
The China State Administration for Market Regulation decided not to prohibit AstraZeneca’s acquisition of FibroGen China, which includes all of FibroGen’s roxadustat assets in China. The transaction is subject to customary closing conditions and deliverables and is expected to close in the third quarter of 2025.
FibroGen and its subsidiary FibroGen China Anemia Holdings, Ltd. will sell all issued and outstanding equity interests of FibroGen International (Hong Kong) Ltd. to AstraZeneca, FibroGen’s long-time commercialization partner for roxadustat in greater China and South Korea. FibroGen will retain rights to roxadustat in the United States, Canada, Mexico, and in markets not already held by AstraZeneca or licensed to Astellas Pharma Inc. in Europe, Japan, and certain other territories.
FibroGen, Inc. furnished a press release announcing its financial results for the quarter ended June 30, 2025; the press release is included as Exhibit 99.1 and an Inline XBRL cover page is included as Exhibit 104.
The company states the press release is furnished (not deemed "filed") for purposes of Section 18 of the Exchange Act and will not be incorporated by reference into other SEC filings. This 8-K does not include numerical financial results within the filing text; investors should review Exhibit 99.1 for the detailed figures and disclosures.